Aug 28, 2023

Mabwell Partners with UNILAB to Market its Adalimumab Biosimilar in the Philippines

➞

Jul 31, 2023

Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Morocco Market

➞

Jul 21, 2023

Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023

➞

Jul 17, 2023

Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

➞

Jul 14, 2023

Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND

➞

Jul 03, 2023

Mabwell Partners with Searle Co Ltd., to Market MAILISHU and 9MW0321 in Pakistan

➞

Jun 27, 2023

Mabwell Established a Licensing and Commercialization Agreement of MAILISHU and 9MW0321 for Egypt Market

➞

Jun 14, 2023

Mabwell Announces the U.S. FDA approval of 9MW3811 for IND

➞

Jun 11, 2023

Launch Conference of MAILISHU, World's Second Prolia® Biosimilar, Held Successfully

➞

May 24, 2023

Mabwell announces NMPA approval of 9MW3811 for IND

➞